----

----

| x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|--------------------------------------------------------------------------------------|

| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|------------------------------------------------------------------------------------------|

| Delaware                                                                                                            | 98-0376008                           |
|---------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| (State or Other Jurisdiction of Incorporation or Organization)                                                      | (I.R.S. Employer Identification No.) |
|                                                                                                                |                                 |
| Hi-Tech Park 2/5 Givat-Ram P.O. Box 39098Jerusalem, Israel  (Address of Principal Executive Offices) | 91390(Zip Code)                      |
|                                                                                                                |                                 |

----

| Large accelerated filer o | Accelerated filer o         |
|---------------------------|-----------------------------|
| Non-accelerated filer o   | Smaller reporting company x |

----

| 3.1 | Certificate of Incorporation (incorporated by reference from our current report on Form 8-K filed March 14, 2011). |
|-----|--------------------------------------------------------------------------------------------------------------------|

| 3.2  | By-laws (incorporated by reference from our current report on Form 8-K filed March 14, 2011). |
|-----------|-----------------------------------------------------------------------------------------------|

| 4.1 | Specimen Stock Certificate (incorporated by reference from our registration statement on Form S-1 filed March 24, 2011). |
|-----|--------------------------------------------------------------------------------------------------------------------------|

| 4.2 | Common Stock Purchase Warrant issued to Attara Fund, Ltd. on January 10, 2011, and transferred to Regals Fund LP on March 11, 2012 (incorporated by reference from our quarterly report on Form 10-Q filed January 13, 2011). |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3* | Amendment No. 1, dated August 28, 2012, to Common Stock Purchase Warrant transferred to Regals Fund LP on March 11, 2012. |
|------|---------------------------------------------------------------------------------------------------------------------------|

| 4.4 | Form of Common Stock Purchase Warrant used in 2010-2011 private placement (incorporated by reference from our registration statement on Form S-1 filed March 24, 2011). |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.5 | Form of Common Stock Purchase Warrant used in 2012 private placements (incorporated by reference from our annual report on Form 10-K filed December 12, 2012). |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6 | Form of Common Stock Purchase Warrant issued to Regals Fund LP (incorporated by reference from Exhibit 10.20 to this Amendment No. 1 on Form 10-K/A filed December 21, 2012). |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.1+ | Consulting Agreement by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008 for the services of Nadav Kidron (incorporated by reference from our current report on Form 8-K filed on July 2, 2008). |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.2+ | Consulting Agreement by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008 for the services of Miriam Kidron (incorporated by reference from our current report on Form 8-K filed on July 2, 2008). |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3+ | Oramed Pharmaceuticals Inc. 2008 Stock Incentive Plan (incorporated by reference from our current report on Form 8-K filed on July 2, 2008). |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4+ | Form of Notice of Stock Option Award and Stock Option Award Agreement (incorporated by reference from our current report on Form 8-K filed on July 2, 2008). |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.5+ | Employment Agreement dated as of April 19, 2009, by and between Oramed Ltd. and Yifat Zommer (incorporated by reference from our current report on Form 8-K filed on April 22, 2009). |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.6 | Consulting Service Agreement dated April 21, 2009, between Oramed Ltd. and ADRES Advanced Regulatory Services Ltd. (incorporated by reference from our current report on Form 8-K filed April 22, 2009). |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.7* | Amendment to Consulting Service Agreement dated February 26, 2012, between Oramed Ltd. and ADRES Advanced Regulatory Services Ltd.  |
|-------|------------------------------------------------------------------------------------------------------------------------------------------|

| 10.8*+ | Clinical Trial Agreement dated September 11, 2011, between Oramed Ltd., Hadasit Medical Research Services and Development Ltd., Miriam Kidron and Daniel Schurr. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.9+ | Clinical Trial Agreement dated July 8, 2009, between Oramed Ltd., Hadasit Medical Research Services and Development Ltd., Miriam Kidron and Itamar Raz (incorporated by reference from our current report on Form 8-K filed July 9, 2009). |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.10 | Agreement dated January 7, 2009, between Oramed Pharmaceuticals Inc. and Hadasit Medical Research Services and Development Ltd. (incorporated by reference from our current report on Form 8-K filed January 7, 2009). |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.11 | Joint Venture Agreement dated June 1, 2010, between Oramed Ltd. and LASER Detect Systems Ltd (now known as D.N.A Biomedical Solutions Ltd.) (incorporated by reference from our quarterly report on Form 10-Q filed July 14, 2010). |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.12 | Manufacturing and Supply Agreement dated July 5, 2010, between Oramed Ltd. and Sanofi-Aventis Deutschland GMBH (incorporated by reference from our current report on Form 8-K filed July 14, 2010). |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.13 | Securities Purchase Agreement between Oramed Pharmaceuticals Inc. and Attara Fund, Ltd., dated as of December 21, 2010 (incorporated by reference from our quarterly report on Form 10-Q filed January 13, 2011). |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.14 | Share Purchase Agreement dated February 22, 2011, between Oramed Ltd. and D.N.A Biomedical Solutions Ltd. (incorporated by reference from our registration statement on Form S-1 filed March 24, 2011). |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.15 | Patent Transfer Agreement dated February 22, 2011, between Oramed Ltd. and Entera Bio Ltd. (incorporated by reference from our registration statement on Form S-1 filed March 24, 2011). |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.16 | Form of Securities Purchase Agreement used in 2010-2011 private placement (incorporated by reference from our registration statement on Form S-1 filed March 24, 2011). |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.17+ | Form of Indemnification Agreements dated March 11, 2011, between Oramed Pharmaceuticals Inc. and each of our directors and officers (incorporated by reference from our definitive proxy statement on Schedule 14A filed on January 31, 2011). |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.18+ | Agreement dated June 21, 2011, with Dr. Michael Berelowitz (incorporated by reference from our current report on Form 8-K filed June 22, 2011). |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.19* | Form of Securities Purchase Agreement used in 2012 private placements. |
|--------|------------------------------------------------------------------------|

| 10.20* | Securities Purchase Agreement used in 2012 private placement with Regals Fund LP. |
|--------|-----------------------------------------------------------------------------------|

| 10.21 | Master Services Agreement dated September 27, 2012, between Oramed Ltd. and Medpace, Inc. (incorporated by reference from our annual report on Form 10-K filed December 12, 2012). |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.22 | MEDPACE Task Order Number: 1 dated September 27, 2012, between Oramed Ltd. and Medpace, Inc. (portions of this exhibit have been omitted pursuant to a request for confidential treatment) (incorporated by reference from our annual report on Form 10-K filed December 12, 2012). |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.23* | Securities Purchase Agreement dated October 30, 2012, between Oramed Pharmaceuticals Inc. and D.N.A Biomedical Solutions Ltd. |
|--------|-------------------------------------------------------------------------------------------------------------------------------|

| 21.1 | Subsidiary (incorporated by reference from our annual report on Form 10-K filed December 12, 2012). |
|------|-----------------------------------------------------------------------------------------------------|

| 23.1 | Consent of Kesselman & Kesselman, Independent Registered Public Accounting Firm (incorporated by reference from our annual report on Form 10-K filed December 12, 2012). |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 23.2*  | Consent of Malone & Bailey, PC,  Independent Registered Public Accounting Firm. |
|-------------|------------------------------------------------------------------------------------------|

| 31.1# | Certification Statement of the Principal Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 31.2# | Certification Statement of the Principal Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 31.3* | Certification Statement of the Principal Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 31.4* | Certification Statement of the Principal Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 32.1** | Certification Statement of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350. |
|--------|------------------------------------------------------------------------------------------------|

| 32.2** | Certification Statement of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350. |
|--------|------------------------------------------------------------------------------------------------|

| 101.1 | The following financial statements from the Company’s annual report on Form 10-K for the year ended August 31, 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Changes in Stockholders’ Equity, (iv)  Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements, tagged as blocks of text and in detail (incorporated by reference from our annual report on Form 10-K filed December 12, 2012). |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | *  | Filed herewith. |
|--------|---------|-----------------|

|   | **  | Furnished with the Initial Form 10-K. |
|--------|----------|---------------------------------------|

|   | #  | Filed with the Initial Form 10-K. |
|--------|---------|-----------------------------------|

|   | +  | Management contract or compensation plan. |
|--------|---------|-------------------------------------------|

----

|   | ORAMED PHARMACEUTICALS INC. |                                  |
|--------|-----------------------------|---------------------------------------|
|   |                        |                                  |   |
|   | By:                         | /s/ Nadav Kidron                 |   |
|   |                        | Nadav Kidron                          |   |
|   |                        | President and Chief Executive Officer |   |
|   |                        |                                  |   |
|   |                        | Date: December 21, 2012               |   |

----

----